Annovis Bio prices 4M shares at $1.50 in registered direct offering

Annovis Bio (ANVS) entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock at a purchase price of $1.50 per share in a registered direct offering. The closing of the offering is expected to occur on or about October 13, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company from the offering are expected to be approximately $6M, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering toward working capital and general corporate purposes.